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DIFFERENT GVHD CLINICAL PROFILE AMONG PATIENTS WHO RE-
CEIVED CORD BLOOD, COMPARED TO THOSE WHO RECEIVED MAR-
ROW OR PERIPHERAL BLOOD
Funke, V.A.M., Nunes, E.C., Medeiros, L., Setubal, D.C., Ruiz, J.,
Oliveira, M.M., Bittencourt, M.A., Bonfim, C., Neto, J.Z.,
Medeiros, C.R., Pasquini, R. Hospital de Clınicas - Federal University
of Parana, Curitiba, Parana, Brazil.
It is well known that transplants from cord blood stem cells have
lower incidence of graft-versus-host disease, which allows proce-
dures with more HLA disparities when compared to marrow. The
objective of this study, however is to determine if there is a different
clinical expression of GVHD beteween receptors of peripheral
blood/marrow versus cord blood.
Patients and Methods: From October 1979 to June 2007, 1530
patients were transplanted at the BMT center of the Federal Uni-
versity of Parana. We retrieved the database of our institution and
divided the patients into two categories. Group one: 1390 patients
who received bm or pb as stem cell source. Group 2: 140 patients
who received cord blood. Main differences between the two goups
are listed at the table below. Statystical Analysis: Kaplan Meier was
used for survival and Fisher test for comparison of categoric vari-
ables. Results: See table 1. Conclusions: 1. There was a lower in-
cidence of lung and oral involvement by chronic GVHD and
a higher incidence of gut involvement on patients who received
CB as compared to PB and Marrow. Furthermore, we did not see
any case of bronchiolitis obliterans in the CB group. 2. There was
less oral and more gut and liver involvement by acute GVHD in
the CB group. 3. Overall incidence of chronic GVHD was lower
for the cord blood group. There were a higher frequency of acute
GVHD grade II-IV among CB recipients, possibly because of the
increased frequency of HLA disparity.CB Marrow/PB: acute and chronic GVHD
Characteristics Group 1 (CB) Group2 (BM/PB) P valueN 140 1390
Age (M) years 6 20
SCT donor 0.0001
related 18 1235
unrelated 122 155HLA 0.0001
compatible 34 1296
1mismatch (A, B,DR) 47 89
other 59 5Male/Female 83/57 841/549
Sex mismatch (male
recipient/female
donor)40 (29%) 289 (21%)A-GVHD 51 (36%) 350 (45%) 0.0385
Grade III-IV 26/51 (51%) 113/350 (32%)
Skin 41 (80%) 297 (85%)
Liver 12 (24%) 141 (40%) 0.0212
Oral 2 (4%) 31 (8%)
Lung 0 4 (1%)
Gut 20 (15%) 89 (25%) 0.0440C-GVHD extensive 13/95 av (14%) 238/1115 av (21%)
severe 4/13 (30%) 95/238 (40%)
C-GVHD organ
Skin 7 (53%) 106 (45%)
Liver 10 (77%) 92 (39%) 0.0084
Oral 2 (15%) 108 (45%) 0.0434
Lung 1 *(7%) 36 (15%)
Gut 6 (46%) 48 (20%) 0.0376Survival (%) 68 (49%) 721 (52%)
Survival (M) days 196 (0–5231) 1028 (0–9078)*BOOP.366
ALLOSPECIFIC EFFECTOR MEMORY T CELLS HAVE DECREASED ABILITY
TO INDUCE ACUTE GVHD
Chen, B.J., Wu, J., DeOliveira, D., Chao, N.J. Duke University Med-
ical Center, Durham, NC.
Several different groups have independently demonstrated that
non-allospecific memory T cells do not induce GVHD. The data
related to the ability of allospecific memory T cells to induce
GVHD have not been conclusive. In order to study this question
more definitely, we have developed a novel GVHD model using
TEa TCR transgenic mice as donors. TEa CD41 TCR transgenic
mice (C57BL/6 background) express a TCR that recognizes the
peptide ASFEAQGLANIAVDKA in the context of I-Ab. This pep-
tide corresponds to positions 52–68 from the alpha-chain of I-E
class II molecules and is expressed in all APCs from H-2b/I-E1
strains such as CB6F1 mice. Titration experiment demonstrated
that as few as 1  105 TEa cells were able to induce lethal
GVHD in lethally irradiated CB6F1 recipients, making it an ideal
model to study the ability of allospecific memory T cells to induce
GVHD. Because sufficient numbers of allospecific memory pheno-
type T cells could not be obtained from the TEa mice or C57BL/6
CD45.1 mice containing TEa cells after priming, we chose the
Rag1-/- model. TEa cells were first parked in Rag1-/- mice and
then were immunized with irradiated CB6F1 cells. Eight weeks
later, TEa cells were harvested from the spleens and effector mem-
ory T cells were obtained after depletion of CD62L1 cells. Many
TEa cells that were parked in the Rag1-/- mice but were not immu-
nized with alloantigens also obtained the effector memory T cell
phenotype. These cells were termed as ‘‘unprimed TEM’’ while
those from primed animals were termed as ‘‘primed TEM’’. Both
primed and unprimed effector memory TEa cells were able to re-
spond to alloantigens in vitro. However, neither primed nor un-
primed effector memory TEa cells was able to induce lethal
GVHD in vivo and all animals in the effector memory T cell groups
survived more than 100 days post transplantation. In contrast, all
naive T cell recipients developed lethal GVHD and died within
35 days after transplantation. These data demonstrate that, similar
to non-allospecific memory T cells, allospecific effector memory
T cells also have decreased ability to induceGVHDwhen compared
with naive T cells. This is an excellent model for us to study the
unique immune response mediated by allospecific memory T cells
in GVHD.367
SURVIVAL AFTER EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR
TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) IS PREDICTED
BY GVHD CLASSIFICATION AS PROPOSED BY NATIONAL INSTITUTE
OF HEALTH (NIH) CONSENSUS CRITERIA
Jagasia, M.1, Stricklin, G.2, Logue, M.1, Lucid, C.1, Fife, H.1,
Mitchell, J.1, Chen, H.3, Hunt, C.1, Kassim, A.1. 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN; 3Vanderbilt University Medical Center, Nashville, TN.
ECP is used in GVHD treatment with variable response. The
clinical phenotype of GVHD associated with ECP responsiveness
is not clear. Subtypes of GVHD proposed by NIH consensus crite-
ria affect survival after allogeneic stem cell transplant (SCT)
(BBMT 2007 Oct; 13(10):1207–15). We hypothesized that survival
after ECP will be determined by NIH subtypes of GVHD.
Methods: Review of patients undergoing ECP for GVHD treat-
ment was done. 55 patients (pts.) were identified and GVHD was
reclassified using NIH criteria. Pts. with acute GVHD (aGVHD)
were graded using Glucksberg criteria. Pts. with overlap or classic
chronic GVHD (cGVHD) were scored using NIH criteria. Overall
survival (OS) was measured from starting ECP. ECP indication was
steroid dependency or refractoriness. Results: Classic aGVHD
(26%), recurrent aGVHD (7%), overlap cGVHD (16%) and classic
cGVHD (51%) accounted for the subtypes. Pts. started ECP at
a median of 216 days after SCT (range, 41 to 2946). The median
number of GVHD recurrences prior to ECP start was 2 (range,
0–6). Pts. with classic cGVHD started ECP significantly later
(145 days vs. 53 days, P\ 0.001), continued it for a longer time
Poster Session II 135(245 vs. 104, P5 0.004) and received more treatments (13 vs. 8, P5
0.006), compared with non-classic cGVHD. The steroid dose (mg/
kg) prior to ECP was lower in classic cGVHD (0.43 vs. 1.21, P\
0.001). 25 of 38 pts. (66%) with classic cGVHD were on #1 mg/
kg of prednisone at ECP start, and 14/17 (82%) of pts. with non-
classic cGVHD were on . 1 mg/kg of steroids (P 5 0.001). For
the entire cohort, the steroid dose at month 2 of ECP was signifi-
cantly less (0.81 vs. 0.38, P 5 0.004). In pts. with classic cGVHD,
there was a trend in decrease in skin subscale scores after 2 months
of ECP. In univariate analysis, OS was superior for classic cGVHD
compared with other subtypes (median survival not reached vs. 78
days, P\ 0.001; 1-yr OS 65% vs. 10%). OS was better for pts.
with steroid dose # 1 mg/kg at start of ECP compared with pts.
on higher dose steroid (median survival not reached vs. 69 days,
P\ 0.001, 1-yr OS 65% vs. 0%). Using Cox regression (adjusted
for steroid dose) non-classic cGVHDwas an independent prognos-
tic feature for poor survival (HR 4.72, 95% CI 1.84–12.41, P 5
0.001). Conclusion: Pts. with classic cGVHD had a superior sur-
vival after ECP compared to other NIH subtypes. Survival after
ECP with other GVHD subtypes is poor and combination of novel
steroid sparing agents with ECP need to be explored.368
THYMOGLOBULIN BINDS NATURAL KILLER CELLS AND INDUCES ACTI-
VATION AND INTERFERON-g PRODUCTION
Dardari, R.1, Dalle, J.-H.2, Menezes, J.1, Cordeiro, P.1,
Champagne, M.1, Duval, M.1. 1CHU Sainte-Justine, Montreal, QC,
Canada; 2Unite d’Immuno-Hematologie Pediatrique, Paris, France.
Background: Antithymocyte globulin (Thymoglobulin, rabbit
IgG) is widely used in hematopoietic stem cell transplantation
(HSCT) to prevent rejection and graft-versus-host disease
(GVHD). A beneficial effect of natural killer (NK)-cell alloreactiv-
ity on HSCT outcome has been described, but only in patients re-
ceiving ATG.We therefore investigated the in vitro effects of ATG
on purified NK cells. Methods: ATG binding to human NK cells
and their activation status were assessed by flow cytometry. NK sur-
face targets for ATGwere determined by competition inhibition as-
says using monoclonal antibodies. Chromium 51 (51Cr) release
assay, annexin V combined to 7AAD staining and CFSE staining
were used to study cytotoxic activity, apoptosis/cell death and pro-
liferation of NK cells, respectively. Interferon (IFN)-g production
was determined by ELISA. Results: ATG, ATG-derived Fab’2
fragments as well as rabbit IgG bound NK cells, and competed
strongly with anti-CD16. ATG enhanced the expression of activa-
tion (CD69, NKG2D) and degranulation (CD107a) markers on
NK cells. ATG competed with CD18 binding and decreased NK
cytotoxicity, which was restored by IL-15. No effects on apopto-
sis/cell death and proliferation were observed. Interestingly,
ATG, ATG-derived Fab’2 fragments as well as rabbit IgG strongly
induced IFN-g production.Conclusions: ATG binds NK cells via
CD16 by its variable and constant regions. The decrease in NK cy-
totoxic activity in vitro, whichmay be explained by CD18 binding, is
restored by IL-15, and contrasts sharply with the induction of acti-
vation, degranulation and IFN-g production. These data support
the hypothesis that ATG treatment is required to observe the ben-
eficial effect of NK cell alloreactivity in HSCT.369
EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR STEROID-RE-
FRACTORY GRAFT-VERSUS-HOST DISEASE (GVHD) IN LOW-WEIGHT
PEDIATRIC PATIENTS. CHANGES IN L-SELECTIN EXPRESSION BY T
LYMPHOCYTES AND CLINICAL OUTCOME
Gonzalez-Vicent, M., Ramirez, M., Perez, A., Sevilla, J., Diaz, M.A.
Hospital Nin˜o Jesus, Madrid, Spain.
Extracorporeal photochemotherapy (ECP) is an emerging treat-
ment modality for steroid-refractory GVHD. The mechanisms by
which ECP works are still not fully understood, and modulation
of dendritic cell subpopulations, a shift of cytokine profile fromTh1 to Th2 and an increase of T-cell regulatory (Treg) cells have
been related to the ECP beneficial effect. We analyzed the clinical
outcome and the effect of ECP on the T lymphocyte subsets of 11
children with steroid-refractory GVHD. ECP was performed by
a continuous-flow cell separator (COBE Spectra). We studied the
L-selectin (CD62L) and the CD45RA expression on CD4 and
CD8 lymphocytes by flow cytometry.We compared the proportion
of each of these 4 subpopulations, as well as the L-selectin positive
and L-selectin negative ones, in samples collected from peripheral
blood before the first (PRE) and after the last (POST) ECP proce-
dures. Results are shown in Table 1.
Complete response (CR) was achieved in six cases. Skin involve-
ment responded in all cases. ECP was associated with minimal side
effects. There was a significant increasing in the CD4/CD8 ratio.
Central memory (CM) cells decreased and effector memory (EM)
cells increased with ECP in CD4 and CD8T–cell subsets. The pro-
portion of L-selectin expressing T lymphocytes significantly dimin-
ished after ECP, both in CD4 and in CD8 cells. L-selectin is an
important T-cell homing receptor for T-cell entry into lymph no-
des via high endothelial venules. Expression of CD62L is rapidly
lost following T-cell receptor activation, leading to exit from the
lymph node into the periphery and sites of inflammation. CD62Lneg
and CD62Lpos also differ in their functional abilities, such as cyto-
kine secretion and cytolytic potential.
Our results suggest that ECP may have an impact in the traffick-
ing patterns of T lymphocytes, redirectioning T cells from lym-
phoid to extralymphoid organs.CD4 and CD8 subsets pre and postECP
PRE POST p valueCD4 subsets
TN (CD62L1CD45RA1) 6.58 ± 2.39 6.18 ± 2.96 0.2
TCM (CD62L1CD45RA-) 58.17 ± 4.49 43.85 ± 4.78 0.02
TEM (CD62L-CD45RA-) 34.64 ± 4.51 46.86 ± 4.89 0.03
TD (CD62L-CD45RA1) 0.6 ± 0.18 3.11 ± 1.46 0.17
CD62Lpos 64.76 ± 4.4 50.03 ± 5.45 0.02
CD62Lneg 35.23 ± 4.4 49.97 ± 5.45 0.02CD8 subsets
TN (CD62L1CD45RA1) 16.95 ± 3.94 12.53 ± 4.05 0.23
TCM (CD62L1CD45RA-) 28.8 ± 4.95 12.27 ± 2.86 0.001
TEM (CD62L-CD45RA-) 46.62 ± 5.79 51.4 ± 4.22 0.14
TD (CD62L-CD45RA1) 11.17 ± 3.34 23.52 ± 4.79 0.01
CD62Lpos 45.75 ± 6.1 24.8 ± 5.34 0.01
CD62Lneg 53.8 ± 6.07 74.92 ± 5.31 0.01370
REDUCED RELAPSE RELATED DEATH (RRD) IN ALTERNATIVE DONOR
TRANSPLANTS WITH EBV/CMV REACTIVATION
Bacigalupo, A., Tedone, E., Soracco, M., Frassoni, F., Van Lint, M.T.
Ospedeale San Martino, Genova, Italy.
Viral infections are a serious diagnostic and therapeutic problem
in patients undergoing alternative donor transplants. We have ana-
lyzed 179 transplants with hematologicmalignancies, ghrafted from
unrelated (n5 139) or family mismatched donors (n5 40): Patients
in this study were alive on day130 and had been monitored weekly
for cytomegalovirus (CMV) reactivation by CMV-antigenemia, and
for epstein barr virus (EBV) reactivation by real time PCR. All pa-
tients received anti-thymocyte globulin 7.5–11 mg/kg for GvHD
prophylaxis together with cyclosporin and methotrextae. The con-
ditioniong regimen was a conventional CY-TBI (n 5 102) or a re-
duced intensity (RIC) thiotepa based regimen (n 5 77). The
diagnosis was acute leukemia (n5 126) or chronic lymphoid or my-
eloid disorder (n 5 53).
Median age was 36 years (11–64) and transplants were performed
between 2000 and 2006. Reactivation of CMV was seen in 78 pa-
tients (44%); EBV reactivation in 118 patients (66%). The average
time to CMV reactivation was day 49 (95%CI day 29–69) and for
EBV it was day 178 (95%CI day 50–105). With an average follow
up of 823 days (95%CI 717–929) the overall actuarial 5 year survival
